The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Open accessAbstract
Adaptive immune resistance is a process in which the cancer changes its phenotype in response to a cytotoxic or proinflammatory immune response, thereby evading it. This adaptive process is triggered by the specific recognition of cancer cells by T cells, which leads to the production of immune-activating cytokines. Cancers then hijack mechanisms developed to limit inflammatory and immune responses and protect themselves from the T-cell attack. Inhibiting adaptive immune resistance is the mechanistic basis of responses to PD-1 or PD-L1–blocking antibodies, and may be of relevance for the development of other cancer immunotherapy strategies. Significance: Several new immunotherapy strategies to treat cancer are based on inhibiting processes through which cancer adapts and evades from an immune response. Recognizing the specific adaptive resistance mechanisms in each case is likely to allow the personalized development of immunotherapies tailored to block how a particular cancer protects itself from the immune system. Cancer Discov; 5(9); 915–9. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 4×
“If there is a sufficient density of T cells in tumors, in particular at the invasive margin, these are likely turned off by inducing adaptive immune resistance, and PD-1–PD-L1 may be dominant in this setting at least in some cancer histologies (17, 18, 39).”
InfluentialSelf-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
Self-citationLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,288
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties
Schwitalla, S., Fingerle, A. A., Cammareri, P., Nebelsiek, T., Göktuna, S. I., Ziegler, P. K., Canli, O., Heijmans, J., Huels, D. J., Moreaux, G., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.012 · Cited by 1,068
Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 998
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., et al. (2015) · Nature · doi:10.1038/nature13848 · Cited by 717 · cited 1×
“25), which has been reported to be a partner of the T-cell immunoglobulin domain and mucin domain-3 (TIM-3) and can be blocked therapeutically using antibodies to result in antitumor activity (26).”
Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003) · European Journal of Immunology · doi:10.1002/eji.200324228 · Cited by 639
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
Loke, P., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931259100 · Cited by 634
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 632
Reversal of the TCR Stop Signal by CTLA-4
Schneider, H., Downey, J., Smith, A., Zinselmeyer, B. H., Rush, C., Brewer, J. M., Wei, B., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 621
Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1005 · Cited by 589
Lee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446
Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells
Santisteban, M., Reiman, J. M., Asiedu, M. K., Behrens, M. D., Nassar, A., Kalli, K. R., Haluska, P., Ingle, J. N., Hartmann, L. C., Manjili, M. H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3343 · Cited by 379
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M., Avramis, E., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 334
Self-citationJuszczynski, P., Ouyang, J., Monti, S., Rodig, S. J., Takeyama, K., Abramson, J., Chen, W., Kutok, J. L., Rabinovich, G. A., & Shipp, M. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706017104 · Cited by 327
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3498 · Cited by 269
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., Gaffal, E., Steitz, J., Tolba, R., Kalinke, U., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0458 · Cited by 256
Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250
Phenotype Switching in Melanoma: Implications for Progression and Therapy
Li, F. Z., Dhillon, A. S., Anderson, R. L., McArthur, G., & Ferrao, P. T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00031 · Cited by 163
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0407 · Cited by 157
Self-citationConstitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells
Kim, J., Myers, A. C., Chen, L., Pardoll, D. M., Truong-Tran, Q. A., Lane, A. P., McDyer, J. F., Fortuno, L. V., & Schleimer, R. P. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0129oc · Cited by 148
Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition
Knutson, K. L., Lu, H., Stone, B. C., Reiman, J. M., Behrens, M. D., Prosperi, C., Gad, E. A., Smorlesi, A., & Disis, M. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1526 · Cited by 136
The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade
Ribas, A., & Tumeh, P. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0933 · Cited by 97
Self-citationDynamic expression of protective CEACAM1 on melanoma cells during specific immune attack
Markel, G., Seidman, R., Cohen, Y., Besser, M. J., Cohen-Sinai, T., Treves, A. J., Orenstein, A., Berger, R., & Schachter, J. (2008) · Immunology · doi:10.1111/j.1365-2567.2008.02888.x · Cited by 50
Ribas, A., & Tumeh, P. C. (2012) · Nature · doi:10.1038/nature11489 · Cited by 11
Self-citation
Cited by
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“The interferon-gamma pathway is emerging as a key player in primary, adaptive, and acquired resistance to checkpoint blockade therapy (Gao et al., 2016; Pardoll, 2012; Ribas, 2015; Shin et al., 2016; Zaretsky et al., 2016).”
Self-citationTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Self-citationMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Self-citation
Metadata
- Authors
- Ribas, A.
- Venue
- Cancer Discovery
- Published
- 2015-09-01
- Volume
- 5
- Issue
- 9
- Pages
- 915-919
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2164001237
- Cited by
- 613
- References
- 48
- FWCI
- 19.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.